Traders Are Skeptical About Bayer’s Chances With Monsanto: Chart

Monsanto Co. closed Wednesday at just $106.76 -- well below Bayer AG’s offer of $128 a share -- as wary traders remained skeptical that the deal will make it to completion. When you place the transaction among other megadeals from the past two years, it doesn’t look good: Both the Pfizer Inc.-Allergan Plc combination and Enterprise Products Partners LP’s bid for Williams Cos. were later terminated. While Anthem Inc.’s $48 billion takeover of Cigna Corp. is still possible, its spread has widened even further in recent months after U.S. regulators sued to block the deal.